tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Intellia Therapeutics upgraded to Neutral from Sell at Citi

Citi analyst David Lebowitz upgraded Intellia Therapeutics to Neutral from Sell with a price target of $39, down from $48. The analyst cites the recent share price decline and the overall potential of the company’s platform for the upgrade. At the current valuation, Intellia’s risk/reward profile is more balanced, the analyst tells investors in a research note. Citi continues to view Intellia’s CRISPR/Cas9 gene-editing platform as a "potentially transformational modality."

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on NTLA:

Disclaimer & DisclosureReport an Issue

1